New hope for hard-to-treat lung cancer? drug combo trial begins

NCT ID NCT07362940

Recruiting now Disease control Sponsor: Henan Genuine Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 23, 2026 · Last updated Jun 16, 2026 · Updated 20 times

Summary

This study tests a new drug (GEN-725) combined with dositinib in 110 adults with advanced EGFR-mutant non-small cell lung cancer that cannot be surgically removed. The goal is to see if the combination is safe and shrinks tumors or slows their growth. This is not a cure; it aims to control the disease and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China
Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Hospital, Shandong cancer prevention and treatment institute)
NOT_YET_RECRUITING

Jinan, China
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, China
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITING

Xiamen, China

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER